Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG plc: Provensis receives FDA approval to commence pilot study with Varisolve

BTG : 06 October, 2006  (Company News)
BTG plc, the global technology commercialisation company, today announced that its subsidiary Provensis Ltd has gained approval from the Food & Drug Administration to commence the first stage of a pilot study in patients in the US with Varisolve, the non-invasive procedure being developed to treat varicose veins.
BTG plc, the global technology commercialisation company, today announced that its subsidiary Provensis Ltd has gained approval from the Food & Drug Administration to commence the first stage of a pilot study in patients in the US with Varisolve, the non-invasive procedure being developed to treat varicose veins.

Successful conclusion of the pilot study, which is expected to begin in September 2002, should, subject to FDA approval, lead to a large scale Phase III pivotal trial.

In the ongoing European Phase III trial, 350 patients have already been treated with Varisolve, and the observed clinical response has been encouraging. 182 patients have received comparative treatments.

Ian Harvey, BTGs chief executive officer, commented:

We are very pleased that Provensis has gained approval to begin clinical studies with Varisolve in the US. In Europe, efficacy data from the ongoing trial will be available by the end of the year, at which time we plan to commence discussions with potential sales and marketing partners. We also expect in the coming months to complete manufacturing arrangements for the Varisolve product.

Varisolve is a virtually painless out-patient treatment for varicose veins being developed to provide an alternative to surgery. Over 150 million people in the US and Europe suffer from varicose veins and could benefit from surgery. Approximately 4 million new cases arise each year.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo